Roberts D A, Bradbury R H, Brown D, Faull A, Griffiths D, Major J S, Oldham A A, Pearce R J, Ratcliffe A H, Revill J
Department of Chemistry, ICI Pharmaceuticals, Mereside, Cheshire, U.K.
J Med Chem. 1990 Sep;33(9):2326-34. doi: 10.1021/jm00171a005.
A series of 1,2,4-triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity, which incorporate (1S,2S)-2-amino-1,3-dicyclohexyl-1-hydroxypropane, statine (Sta), and (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy-pentanoic acid (ACHPA) transition-state mimetics, have been prepared. Structure-activity relationships for renin inhibitory activity in the series are consistent with the 2-[8-isobutyl-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-yl]-3-(3 pyridyl)propionic acid moiety 10b acting as a non-peptidic replacement for the P4-P2 (Pro-Phe-His) residues of the natural substrate angiotensinogen. Compounds 12m, 12o and 12q were potent inhibitors of partially purified human renin (IC50 values 1.7, 6.8, and 3.7 nM, respectively), and also effectively lowered blood pressure in anesthetized, sodium depleted marmosets following intravenous administration. On oral administration however, no blood pressure lowering activity could be detected, and absorption studies in bile duct cannulated rats indicate that this may be due primarily to poor oral absorption, rather than rapid biliary excretion. The reason for the observed poor oral activity is not clear, but it seems unlikely that poor aqueous solubility or metabolic instability to gut enzymes are rate-determining, and other factors such as high molecular weight may also be very important.
已制备出一系列具有人肾素抑制活性的1,2,4-三唑并[4,3-a]吡嗪衍生物,这些衍生物包含(1S,2S)-2-氨基-1,3-二环己基-1-羟基丙烷、他汀(Sta)和(3S,4S)-4-氨基-5-环己基-3-羟基戊酸(ACHPA)过渡态模拟物。该系列中肾素抑制活性的构效关系与2-[8-异丁基-6-苯基-1,2,4-三唑并[4,3-a]吡嗪-3-基]-3-(3-吡啶基)丙酸部分10b作为天然底物血管紧张素原的P4-P2(脯氨酸-苯丙氨酸-组氨酸)残基的非肽替代物一致。化合物12m、12o和12q是部分纯化的人肾素的有效抑制剂(IC50值分别为1.7、6.8和3.7 nM),并且在静脉给药后能有效降低麻醉的、缺钠的狨猴的血压。然而,口服给药时未检测到降压活性,在胆管插管大鼠中的吸收研究表明,这可能主要是由于口服吸收不良,而非胆汁快速排泄。观察到口服活性差的原因尚不清楚,但水溶性差或对肠道酶的代谢不稳定性似乎不太可能是限速因素,其他因素如高分子量也可能非常重要。